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To evaluate current guidelines criteria for inclusion of women in special ‘breast cancer family history’ surveillance programmes,
records were reviewed of women referred to Scottish breast cancer family clinics between January 1994 and December 2003 but
discharged as at ‘less than ‘moderate’ familial risk’. The Scottish Cancer Registry was then interrogated to determine subsequent age-
specific incidence of breast cancer in this cohort and corresponding Scottish population figures. Among 2074 women, with an average
follow-up of 4.0 years, 28 invasive breast cancers were recorded up to December 2003, where 14.4 were expected, a relative risk
(RR) of 1.94. Eleven further breast cancers were recorded between January 2004 and February 2006 (ascertainment incomplete for
this period). The overall RR for women in the study cohort exceeded the accepted ‘cutoff’ level (RR¼ 1.7) for provision of special
counselling and surveillance. The highest RR was found for the age group 45–59 years and this group also generated the majority
of breast cancers. The National Institute for Clinical Excellence (‘NICE’) guidelines appear to be more accurate than those of the
Scottish Intercollegiate Guidelines Network (‘SIGN’) in defining ‘moderate’ familial risk, and longer follow-up of this cohort could
generate an evidence base for further modification of familial breast cancer services.
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A family history of breast cancer is recognised as a risk factor for the
disease. Most efforts to quantify that risk rely upon two retrospective
studies (Claus et al, 1991; Collaborative Group on Hormonal Factors
in Breast Cancer, 2001), both of which provide a range of estimates,
based on the number of affected close relatives and their ages at
diagnosis. These estimates, however, are derived from rather small
numbers of women in some of the specific risk categories and have
wide confidence intervals. The National Institute for Clinical
Excellence (NICE) (2004) guideline on familial breast cancer
concludes that ‘validation of risk assessment models is urgently
needed’. It is universally accepted that a woman under 50 years who
has three or more close relatives affected with breast cancer (one at
least being a first-degree relative or second degree if on her father’s
side of the family) is at sufficiently increased risk to justify special
surveillance, with the object of detecting breast cancer early in
women too young to be included in the National Breast Screening
Programme (NBSP). If there are only two close relatives affected,
SIGN guidelines stipulate that both must have been under 60 years at
diagnosis, but NICE (both the 2004 version and the 2006 update)
applies no such age restriction. Under either NICE or SIGN criteria,
if there has been only a single first-degree relative affected, risk to
sister or daughter is not considered to be significantly increased
unless age at diagnosis was less than 40 years. Both guidelines also
take account of ovarian cancer among relatives, attaching slightly
greater weight to it than to breast cancer in assessing familial risk. A
prospective evaluation of five different protocols for prediction of
breast cancer risk from family history and other criteria (Amir et al,
2003) concluded that the most commonly applied models tended to
underestimate risk, particularly for those at the lower end of the
familial risk spectrum but, again, numbers were limited. We have
therefore embarked on a prospective survey of cancer incidence
among a large cohort of asymptomatic women discharged from
breast cancer family clinics because their risk levels, based on
reported family histories, were judged insufficient to warrant
enrolment in special surveillance programmes.
PATIENTS AND METHODS
Since 1994, clinical services for familial breast cancer have been
provided for the whole of Scotland by a network comprising four
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major centres in Aberdeen, Dundee, Edinburgh and Glasgow,
involving close collaboration between medical genetics, diagnostic
radiology and breast surgery units, with support from the
Information Services Division (ISD) of the NHS Scotland Common
Services Agency and the Scottish Cancer Registry. Two of the
centres operate ‘one-stop’ clinics staffed by geneticists, breast
surgeons and radiologists. The others provide comparable, but
sequential, services in separate genetics and breast surgery clinics.
In all four centres practice is based on guidelines formulated by the
Scottish Office Home and Health Department (1998) and
incorporated into Scottish Intercollegiate guidelines Network
(SIGN) Guideline 29, 1998. These set a threshold, for the definition
of ‘moderate’ familial risk, the major criteria being summarised
above. Women referred to a breast cancer family service whose
family histories meet or exceed these criteria are offered regular
surveillance from age 35 (or 5 years younger than the earliest age
of disease onset in a relative). Otherwise, they are discharged to
primary care with reassurance, advice on being ‘breast aware’,
encouragement to take advantage of the National Breast Screening
Programme (NBSP) from age of 50 and a request to notify the
cancer genetics service should any new breast or ovarian cancers
occur within the family. The threshold requirements are in line
with those proposed in the majority of published recommenda-
tions (Public Health Genetics Unit, 1998; Watson et al, 1999; Eccles
et al, 2000; Haites et al, 2002; Breakthrough Breast Cancer, 2004;
Nelson et al, 2005) but differ from NICE guidelines which remove
any age-at-diagnosis restriction in the case of two affected
relatives.
With local approval for audit purposes, the records of the four
Scottish breast cancer family services were scrutinised to identify
all referred women whose risk had been assessed, as below the
‘moderate’ threshold over the 10-year period from January 1994 to
December 2003. Then, with consent from the Privacy Committee,
Scottish Cancer Registry records were checked to detect any
cancers recorded in this cohort of individuals. For breast and
ovarian cancers, confirmation and further pathological details
were sought from case notes.
For each woman referred to a cancer family clinic, but not
offered continuing surveillance, the period elapsing between
discharge from the service and December 2003 was calculated
and, from that and the date of birth, the number of woman years of
observation within one or more 5-year age spans (35–39, 40– 44
and so on) was derived. The data were aggregated to give the total
number of woman years of observation per 5-year age group and
the corresponding ‘expected’ numbers of breast cancers were
obtained from Scottish Cancer Registry figures, which report
annual incidence for the same age groups. Where a breast or
ovarian cancer had been recorded, the precise details of family
history were re-checked in every case from cancer family clinic
records. Cancers registered after December 2003 were noted and
checked as above. Because registration is still incomplete for that
period, these cases cannot be included in calculations of absolute or
relative age-specific incidence but can be added to the earlier cases
to record age distribution of cancers, their clinical and pathological
characteristics and the proportions that would have met NICE
criteria for inclusion in special surveillance programmes.
RESULTS
The principal findings are summarised in Table 1a and b and
Figure 1. Within the main 10-year study period, 28 invasive breast
cancers were recorded in 26 women out of the total cohort of 2074.
The expected number was 14.4, giving an overall relative risk (RR)
of 1.94 (95% CI¼ 1.3–2.8). As shown in Figure 1, the RR was not
uniform for all age groups, the highest (42.8) being for the 50– 54
year olds. The 11 further breast cancers diagnosed since December
2003 are listed in Table 1b and included in Figure 2.
Two women had suffered synchronous bilateral breast cancers,
in each case both tumours being detected at first NBSP
mammogram at the age of 50 years. One had a family history
that would have placed her in the ‘NICE moderate’ risk category
(sister diagnosed at the age of 46 years, paternal grandmother in
her 70’s). The other had only one affected relative, her mother,
diagnosed at the age of 70 years. She would therefore have been
considered below threshold risk level for surveillance under any
extant guidelines.
In addition to the breast cancers recorded in Table 1a and b,
there were three instances of ductal carcinoma in situ (DCIS) and
one patient in whom an unsuspected second focus of invasive
ductal cancer was identified by the pathologist in the mastectomy
specimen following surgery for a symptomatic cancer. Although
this was considered a second primary, that could not be proved
and it has not been treated as such in the present report. One
additional case of DCIS was recorded in 2005 and has been
excluded from calculations. More than half of all breast cancers
Table 1a Data on breast cancers among 2074 women discharged from the Scottish breast cancer family clinics, January 1994 to December 2003
Breast cancers expected
Breast cancers recorded
Women-years of F/U: (Population data) (Total cohort) (Excluding NICE ‘moderate risk’)
Ageo35 843 0.25 0 0
35–39 1341 0.8 1 1
40–44 1552 1.9 2 1
45–49 1522 2.7 4 3
50–54 1405 3.9 11 8
55–59 846 2.5 5 5
60–64 454 1.4 2 0
65+ 320 0.95 3 1
Total 8283 14.4 28 19
(95% CI¼ 18.61–40.47) (95% CI¼ 11.44–29.67)
Node negative Node positive
Invasive ductal carcinoma 13 6
Invasive lobular carcinoma 2 1
Invasive tubular carcinoma 4 0
Mixed types 2 0
Screen-detected¼ 18, Symptomatic¼ 10
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were diagnosed at clinical or mammographic screening – mainly
through the NBSP, but three at one of the multi-disciplinary breast
cancer family clinics, where policy (until the year 2004) had been
to see all women referred, even where their risk had been evaluated
and the decision already taken to discharge them following that
single visit. Since 2004, women whose risk has been assessed as
below the ‘moderate’ threshold are no longer seen at the multi-
disciplinary clinic and are not offered clinical examination or a
mammogram before discharge.
Twelve of the 39 tumours (31%) occurred in women whose
family histories would have placed them in the ‘moderate’ risk
category had NICE, rather than SIGN guidelines been applied –
that is, they had two affected close relatives (one first degree) at
least one of whom had been over 60 at diagnosis. A re-examination
of the family histories of our total cohort shows that only 10%
would have been reclassified as ‘moderate risk’ under NICE criteria
(‘NICE moderate’ subgroup).
There were three epithelial ovarian cancers (one each of serous,
mucinous and endometrioid type) and one borderline ovarian
Table 1b Breast cancers diagnosed in the study cohort since December,
2003
Age
o35 0
35–39 0
40–44 1 (NICE ‘moderate risk’)
45–49 1
50–54 2
55–59 4
60–64 3 (Two NICE ‘moderate risk’)
Total 11 7 screen-detected, 4 symptomatic:
10 invasive ductal, 1 papillary
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Figure 1 Age-group distribution of 28 invasive breast cancers recorded by the Scottish Cancer Registry from January 1994 to December 2003 among
2074 women discharged from the Scottish Breast Cancer Family clinics as being at less than ‘threshold’ level of risk: the same data but excluding cancers
occurring among women whose risk would have been above the threshold under 2004 NICE guidelines (‘NICE moderate’ group) and expected distribution
of breast cancers among 2074 unselected Scottish women with the same age distribution.
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Figure 2 Age distribution of 39 invasive breast cancers recorded up to February 2006 in the study cohort (records incomplete beyond December 2003
so comparison with expected numbers would be invalid).
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tumour. Only two ovarian cancers would have been expected but
numbers are too small to draw any inference as yet.
DISCUSSION
The overall RR found in this study approached 2.0, appreciably
higher than the level of 1.7, which NICE and most other guidelines
accept as the threshold above which women should be offered
enrolment in a surveillance programme. Given that Cancer
Registry data can never be 100% complete since, for example,
any cancers occurring in members of our study cohort who had
left Scotland would not be recorded, the RR we have calculated is a
conservative figure. Furthermore, it is consistent with the findings
of the very large reanalysis of epidemiological studies on familial
breast cancer (Collaborative Group on Hormonal Factors in Breast
Cancer, 2001), which cites a RR of almost two for women with one
relative affected between the ages of 40 and 54 years. It is also in
keeping with the conclusion of Amir et al (2003) that most
currently applied algorithms underestimate the RRs associated
with ‘weak’ family histories.
When NICE criteria are applied, 9 of the 28 cancers recorded
before the end of the year 2003 were in women at ‘moderate’ risk.
This applies to 12 cancers (in 11 women) from the total series of 39
(30.8%). These potentially ‘moderate risk’ women thus appear to
be over-represented among those who subsequently developed
breast cancer, relative to their numbers in the study cohort. If they
are excluded, the overall RR falls to 1.32 (95% CI¼ 0.8–2.1).
However, 6 of the 11 NICE ‘moderate risk’ group were 60 or over at
discharge from the cancer family service, whereas women of that
age represented less than 10% of our total study population.
Elderly people will, of course, have more elderly close relatives
and, as breast cancer is an age-related disease, they may have more
affected relatives without necessarily implying an increased
familial risk.
Different issues arise in relation to the other end of the age
spectrum. Where the family history is not strong, the chances of a
major gene mutation (BRCA1 or BRCA2) being present are small
and so too is the risk of very early-onset breast cancer. The RR in
our cohort for women up to the age of 44 years is only 1.05, even if
the single ‘NICE moderate’ patient is included. This age group
comprised 45% of our total cohort and, while little weight can be
attached to just three cancers, the findings suggest that NICE
referral criteria are satisfactory for women under the age of 45
years, that is, the incidence of breast cancer among those who do
not ‘qualify’ for special surveillance through a cancer family clinic
is no higher than expected for the general population.
Our findings are most relevant to women aged 45–59 years.
They accounted for 46% of our total woman years of follow-up but
generated 71% of the breast cancers (84% if the NICE ‘moderate
risk’ cases are excluded), and had a RR of 2.2 (95% CI¼ 1.4–3.4)
or 1.79 (95% CI¼ 1.00–2.85) with the exclusion. Given that all but
3 of these 27 cancers had actually been diagnosed by the age of 56
years, there is a reasonable expectation that most would have been
screen detected in a surveillance programme that provided regular
mammography upto the age of 55 years. In fact, 10 of the 13
invasive breast cancers (77%) diagnosed in women from this
cohort between the ages of 50 and 52 years were screen-detected,
which contrasts with the corresponding figure from ISD of only
41% for the same age group in the unselected Scottish population
(Po0.02), suggesting that women who had been discharged from a
breast cancer family clinic were particularly motivated to attend
for breast screening from the age of 50 years and/or that their
tumours were slow growing and hence more amenable to screen
detection. NICE criteria include a stipulation that ‘moderate’ risk
means at least a 3% absolute risk of breast cancer between the ages
of 40 and 50 years. Restricting analysis to the 1994–2003 cohort,
we find that, even excluding the ‘NICE moderate’ cases, and
assuming that half of the cancers detected at the age of 50 or 51
years would have been diagnosed by the age of 50 years in an
appropriate screening programme, the cumulative risk over the 5
years from the age of 45 years was 2.3%, whereas the correspond-
ing figure for the 10-year age span 45–55 (with the same
assumption that half the cancers diagnosed at the age of 56 years
might have been detected by the age of 55 years through screening)
is 4.8%. Overall, these findings suggest that, for women aged
45–55 years, family history criteria for inclusion in breast cancer
surveillance programmes should be kept under review.
The effect of the breast cancers diagnosed after discharge
from the family history clinics would have been to raise the
estimated familial risk level for close relatives, in many cases
making them eligible for inclusion in regular surveillance
programmes. In two instances, where the original family history
was of one first-degree relative diagnosed over the age of 40 years,
the onset of breast cancer in our patient was followed within 1 year
by the same diagnosis in a sister, also at an early age, transforming
both families to the upper end of the ‘moderate risk’ category.
Nevertheless, despite the advice on discharge from the cancer
family clinics, it was noted that very few of the newly occurring
cancers had been reported to the breast cancer family clinics,
either by the patients themselves or via the symptomatic breast
services.
The practical implications of this study will not necessarily
mean an increased workload for breast cancer family history
surveillance programmes. While adopting current NICE rather
than SIGN criteria means an increase in the proportion of
referrals leading to inclusion in a surveillance programme. The
actual increase is small since 60–75% of all referred women
are already enrolled in special screening. Only 10% of those
previously judged to be below threshold risk level (i.e., 2.5–4% of
all referrals) will now be added to the surveillance programme.
Although that is not a trivial consideration, the added workload
(and cost) could be offset if it can be confirmed that many
women currently enrolled at the age of 35 or 40 years may safely
delay entry until 45 years. For at least some of those at ‘moderate’,
rather than ‘high’ risk, screening from age 45 to 55 years,
perhaps at intervals of 18 rather than 12 months, may prove to
be cost-effective and it should be borne in mind that this risk
group comprises the bulk of cancer family referrals. Hence, a
reduction of some 5% in total workload should be achievable by
this approach.
For the present, our findings support the NICE modification of
threshold for ‘moderate risk’ – that is, removing any ‘age at
diagnosis’ restriction where there are two affected close relatives.
To extend our findings and to generate evidence that might
justify further adjustments to family history criteria for enrolment
in special surveillance programmes, we propose to continue
follow-up of the cohort of women described in this report,
since each additional year provides a further 2000 women years
of observation and the incomplete data from 2004 onwards
show that accrual of breast cancers is continuing at an
undiminished rate.
Longer follow-up may also allow us to address the crucial
question of whether special surveillance programmes for women
with a family history of breast cancer confer any advantage in
terms of outcome. It is impractical to assign such women to a
randomised trial, deliberately excluding some from clinical/
mammographic screening, but our cohort may generate compar-
able, albeit more limited, data.
Recent findings in relation to the identification of ‘low
penetrance’ breast cancer susceptibility alleles (Easton et al,
2007; Hunter et al, 2007) may lead to more precise definition of
individual familial risks and it will be of great interest to establish
how the distribution of these alleles correlates with breast cancer
incidence across a wide spectrum of risk as determined by family
history.
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